anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Synthetic plant activators represent a promising novel class of green pesticides that can triggering endogenous plant immunity against pathogen invasion. In our previous study, we developed a series of fluorinated compounds capable of eliciting disease resistance in plants; however, the underlying regulatory mechanisms remained unclear. In this study, we systematically investigated the mechanism of plant immune activation using four synthetic plant activators in Arabidopsis thaliana (A. thaliana), including two fluorine-substituted and two non‑fluorine-substituted molecules. Our findings revealed that the fluorinated compounds exhibited superior disease resistance activity compared to the non-fluorinated molecules. Gene expression analysis in systemic acquired resistance (SAR)- and induced systemic resistance (ISR)-related pathways demonstrated that fluorine substitution effectively regulated both SAR- and ISR-pathway activation, highlighting the distinct roles of fluorine in modulating the plant immune system. Notably, the prolonged ROS burst was observed in chloroplasts following treatment with all four plant activators, contrasting with the transient ROS burst induced by natural elicitors. These results provide insights into the unique mechanisms underlying synthetic plant activator-induced plant immunity. Furthermore, comprehensive proteomic analysis revealed a robust immune response mediated by fluorine-substituted plant activators. These findings offer novel insights into the role of fluorine substitution in SAR- and ISR-associated immune signaling pathways and their distinct impact on ROS production within chloroplasts.
Kidney stone, one of the oldest known diseases, has plagued humans for centuries, consistently imposing a heavy burden on patients and healthcare systems worldwide due to their high incidence and recurrence rates. Advancements in endoscopy, imaging, genetics, molecular biology and bioinformatics have led to a deeper and more comprehensive understanding of the mechanism behind nephrolithiasis. Kidney stone formation is a complex, multi-step and long-term process involving the transformation of stone-forming salts from free ions into asymptomatic or symptomatic stones influenced by physical, chemical and biological factors. Among the various types of kidney stones observed in clinical practice, calcareous nephrolithiasis is currently the most common and exhibits the most intricate formation mechanism. Extensive research suggests that calcareous nephrolithiasis primarily originates from interstitial subepithelial calcified plaques and/or calcified blockages in the openings of collecting ducts. These calcified plaques and blockages eventually come into contact with urine in the renal pelvis, serving as a nidus for crystal formation and subsequent stone growth. Both pathways of stone formation share similar mechanisms, such as the drive of abnormal urine composition, involvement of oxidative stress and inflammation, and an imbalance of stone inhibitors and promoters. However, they also possess unique characteristics. Hence, this review aims to provide detailed description and present recent discoveries regarding the formation processes of calcareous nephrolithiasis from two distinct birthplaces: renal interstitium and tubule lumen.
Patients should be told that the antianginal efficacy of Isosorbide mononitrate extended-release tablets can be maintained by carefully following the prescribed schedule of dosing. For most patients, this can be accomplished by taking the dose on arising.

As with other nitrates, daily headaches sometimes accompany treatment with ISMN. In patients who get these headaches, the headaches are a marker of the activity of the drug. Patients should resist the temptation to avoid headaches by altering the schedule of their treatment with ISMN, since loss of headache may be associated with simultaneous loss of antianginal efficacy. Aspirin or acetaminophen often successfully relieves ISMN induced headaches with no deleterious effect on ISMN antianginal efficacy.

Treatment with ISMN may be associated with light-headedness on standing, especially just after rising from a recumbent or seated position. This effect may be more frequent in patients who have also consumed alcohol.

Patients should be advised that they may pass empty matrix "ghosts" (tablets) via colostomy or in the stool, and that this is of no concern since the active medication has already been absorbed.
This is a randomized, placebo-controlled, blinded study of intravenous N-acetylcysteine (NAC) for the prevention of postoperative myocardial dysfunction and apoptosis in infants undergoing arterial switch for D-transposition of the great arteries. Subjects will be age 0-3 months, and no distinctions will be made based on gender or race. Infants operated before 36 weeks post-conceptional age or with birth weight less than 1.8 kilograms will be excluded. Informed consent will be obtained from the patient's parent by one of the investigators in the hospital before the infants undergo surgery.

Subjects will be randomized based on a block randomization scheme to receive placebo or NAC infusion, starting with a loading dose 1 hour prior to surgery. If there is any concern by the ICU physician that the patient is developing toxicity to the medicine, the study drug will be discontinued and the patient removed from the study. Patients will have a thermodilution catheter placed during surgery for postoperative direct measurement of cardiac output. Endomyocardial biopsy will be performed by the surgeon pre- and post-bypass for measurement of markers of apoptosis. Postoperatively, patients will continue to receive an infusion of IV NAC for 24 hours. Blood draws will be through existing arterial and central venous catheters. Serum labs collected will include serial lactate values (already collected routinely), liver and renal function tests, CK-MB and troponin-I levels as a marker of myocardial injury, and S100b level as a marker of brain injury. Total additional blood removed for research purposes will be less than 15 mL. Cardiac output will be measured serially by thermodilution. Serial transthoracic echocardiography will be used to determine left ventricular function. Inotropic score, duration of mechanical ventilation, length of ICU stay, and length of hospitalization will be recorded.
The participants will get written feedback about their physical activity level after the baseline, and after 3, 6, 9 and 15 months of baseline compared to the current physical activity recommendations. Feedback will be created to illustrate participants´ activity level during the measurement week combining also the information from the diary. Feedback will be posted home and don´t include face to face interaction. As an incentive for participation, participants will also have opportunity to attend a body composition analyze and get short interpretation (15 min) of their own results in the research center.
Families randomized to enhanced standard intervention (ESI) will be given informational materials from the American Heart Association on cardiovascular health. ESI includes self-management which is standard care. At 12, 24, and 36 months they will be asked to return for in person follow-up to collect bio measures again and complete follow up surveys at the UCI FQHC in Santa Ana or during scheduled community data collection events. All adults will be asked to take their blood pressure with the device once a week.
Refer to Table 2 and Table 3 to calculate the dose (mg) based on the patient's weight in kg; multiple vials of ACETADOTE may be required [see Dosage and Administration (2.5)]. Discard any unused portion left in the vial. 

Because ACETADOTE is hyperosmolar (2,600 mOsmol/L), ACETADOTE must be diluted in the recommended volume of sterile water for injection, 0.45% sodium chloride injection (1/2 normal saline), or 5% dextrose in water prior to intravenous administration. The total injection volume will vary based on the patient's weight and chosen dosage regimen (i.e., three-bag or two-bag) [see Dosage and Administration (2.5), Warnings and Precautions (5.2)]. 

The choice of diluent should be based on the individual patient's clinical status, concurrent medical conditions, and institutional protocols. The treating clinician should assess each case individually and consult with their pharmacy if there are any concerns about the appropriate diluent choice. In general, 0.45% normal saline is the preferred diluent because it provides a more consistent osmolarity profile, reduces the amount of free water delivered to the patient, and better approximates physiologic fluids than 5% dextrose in water or sterile water for injection. However, consider 5% dextrose in water or sterile water for injection if sodium load is a concern for the patient. 

Dilution of ACETADOTE in each of these three solutions results in different osmolarity of the acetylcysteine solution for intravenous administration (see Table 1 for examples of different osmolarity of the solution depending on the type of solution and the ACETADOTE concentration). 

The choice of diluent should be based on the individual patient's clinical status, concurrent medical conditions, and institutional protocols. The treating clinician should assess each case individually and consult with their pharmacy if there are any concerns about the appropriate diluent choice. In general, 0.45% normal saline is the preferred diluent, as it provides a more consistent osmolarity profile, reduces the amount of free water delivered to the patient, and better approximates physiologic fluids than 5% dextrose in water or sterile water for injection. 

Visually inspect for particular matter and discoloration prior to administration. The color of the diluted solution ranges from colorless to a slight pink or purple once the stopper is punctured (the color change does not affect the quality of the product). The diluted solution can be stored for 24 hours at room temperature. Discard the unused portion. If a vial was previously opened, do not use for intravenous administration.
FIELD: medicine. 
     SUBSTANCE: invention refers to medicine, namely to therapy, balneotherapy. The method involves prescribing keeping diet No.8, taking radon baths. Individual patient's sensitivity to radon procedures shall be determined at first. That is ensured by measuring blood pressure and pulse rate on an empty stomach before taking a bath. Then the patient takes a bath with mineral water of thermal radon sources at water temperature approximately 38°C and has a rest for 30 minutes. Then blood pressure and pulse rate are measured once more. If observing pulse being unchanged or changed by ±10 beat/min and systolic and/or diastolic blood pressure being changed by ±10 mm Hg, the type I reaction is stated in the patient. If pulse is found to be changed by ±20 beat/min, and systolic and/or diastolic blood pressure has been changed by ±15 mm Hg, the type II reaction is observed. If pulse has been changed by ±30 beat/min, and systolic and/or diastolic blood pressure has been changed by ±20 mm Hg, the type III reaction is observed. The type I reaction requires the following bath-taking scheme: the first procedure - 5 minutes, the second one - 8 minutes, the third one - 10 minutes, all the following procedures - for 15 minutes. The type II reaction requires the following bath-taking scheme: the first procedure - 5 minutes, the second one - 8 minutes, the third one - 10 minutes, all the following procedures - for 12 minutes. The type III reaction requires the following bath-taking scheme: the first procedure - 5 minutes, the second one - 8 minutes, the third one - 10 minutes, all the following procedures - for 10 minutes. Radon bath is taken for two days running followed by the two-day pause. Before noon, two hours after breakfast, the patient moderately drinks radon water 200 ml, swims in the swimming pool for 40 minutes and undergoes a detensor-therapy. During afternoon, two hours after dinner, the patient moderately drinks radon water 200 ml and takes a bath with radon water; then a resonant-acoustic fluctuations procedure follows. The therapeutic course includes 10-15 baths. On the bath-free days, intestinal lavage is prescribed before noon, and hydromassage and body and face thalassotherapy are used during afternoon. 
     EFFECT: method provides manifested body weight reduction ensured by normalising action of external respiratory function and lipid metabolism. 
     3 cl, 1 tbl
Sézary syndrome (SS) is an aggressive leukemic expansion of skin-derived malignant CD4+ T cells. Drug monotherapy often results in disease relapse because of the heterogenous nature of malignant CD4+ T cells, but how therapies can be optimally combined remains unclear because of limitations in understanding the disease pathogenesis. We identified immunologic transitions that interlink mycosis fungoides with SS using single-cell transcriptome analysis in parallel with high-throughput T-cell receptor sequencing. Nascent peripheral CD4+ T cells acquired a distinct profile of transcription factors and trafficking receptors that gave rise to antigenically mature Sézary cells. The emergence of malignant CD4+ T cells coincided with the accumulation of dysfunctional monocytes with impaired fragment crystallizable γ-dependent phagocytosis, decreased responsiveness to cytokine stimulation, and limited repertoire of intercellular interactions with Sézary cells. Type I interferon supplementation when combined with a monoclonal antibody targeting the chemokine receptor type 4 (CCR4), unleashed monocyte induced phagocytosis and eradication of Sézary cells in vitro. In turn, coadministration of interferon-α with the US Food and Drug Administration-approved anti-CCR4 antibody, mogamulizumab, in patients with SS induced marked depletion of peripheral malignant CD4+ T cells. Importantly, residual CD4+ T cells after Sézary cell ablation lacked any immunologic shifts. These findings collectively unveil an auxiliary role for augmenting monocytic activity during mogamulizumab therapy in the treatment of SS and underscore the importance of targeted combination therapy in this disease.
The present invention relates to improved methods for filling the skin for cosmetic or medical purposes. Compositions comprising carboxymethyl cellulose (CMC), polyethylene oxide (PEO) and calcium ions can be made and have physical properties that depend on the amounts and types of CMC, PEO, and calcium ions to form ioniclaly cross-linked gels. Compositions can be formed into microspheres, coascervates, gels, or membranes. Gels, microspheres and coascervates can be injected directly into a site for dermal filling. Membranes can be surgically introduced, where they swell to form hydrated gels. After introduction, the dermal filler persists for a period of time and then can disintegrate and be removed from the body.
BACKGROUND: This study aimed to evaluate the efficacy and safety of adjuvant tirofiban in patients with acute basilar artery occlusion due to large-artery atherosclerotic (LAA) receiving endovascular therapy (EVT).
METHODS: This was a non-randomized, multicenter study using data from the Endovascular Treatment for Acute BASILAR Artery Occlusion (BASILAR) registry. Patients with acute basilar artery occlusion due to LAA within 24h of symptom onset who underwent EVT were included. Patients were divided into tirofiban and non-tirofiban groups according to whether tirofiban was used. The primary outcome was the ordinal modified Rankin scale score at 90 days. Safety outcomes were mortality within 90 days and symptomatic intracranial hemorrhage (sICH) within 48 h.
RESULTS: A total of 417 patients were included, of whom 275 patients were in the tirofiban group and 142 patients in the non-tirofiban group. Compared with patients in the non-tirofiban group, patients in the tirofiban group were associated with a favorable shift in functional outcome at 90 days (6[4-6] vs 5 [2-6]; adjusted common OR, 2.51; 95 % CI, 1.64-3.83). The mortality was lower in the tirofiban group than the non-tirofiban group (40.7 % vs 58.5 %; adjusted OR, 0.35; 95 % CI, 0.21-0.56). The rate of sICH was 12.2 % in the non-tirofiban group and 5.2 % in the tirofiban group (adjusted OR, 0.37; 95 % CI, 0.17-0.80; P = 0.012).
CONCLUSION: Tirofiban plus EVT might improve functional outcomes with a good safety for patients with acute basilar artery occlusion due to LAA. The results need to be confirmed in a randomized trial.
Reproducibility of optimal 4DCT acquisition method determined from cohort 1 tested with cohort of 18 study subjects. Three 4DCT images acquired, all with acquisition method determined from cohort 1. Cohort also receives two spiral-mode 4DCT acquisitions.
The invention discloses a sanitary wet tissue for cleaning private parts and a preparation method of the sanitary wet tissue. The sanitary wet tissue is mainly prepared by use of a wet tissue carrier, namely non-woven fabric, RO pure water, traditional Chinese medicine extracts, compound essential oil, additives and a pH regulator, wherein the wet tissue carrier is immersed with the RO pure water, the traditional Chinese medicine extracts, the compound essential oil, the additives and the pH regulator; the traditional Chinese medicine extracts include such components as lobedfruit schizocapsarhizome, hypericum patulum thunb. var. henryi veitch, sophora japonica twig, prepared black bean, semen cassiae sophera, glycyrrhiza pallidiflora maxim and arabispendula l. var. hypoglauca franch; the compound essential oil includes such components as geranium essential oil, lavender essential oil, frankincense essential oil, myrrh essential oil, chamomile essential oil and needle juniper essential oil. The sanitary wet tissue for cleaning private parts is suitable for the private parts of a human body, and applicable to cleaning before and after sexual lives, cleaning after defecation and daily care, and can be used by ordinary men and women. Added with the traditional Chinese medicine extracts and the compound essential oil, the sanitary wet tissue is capable of sterilizing, diminishing inflammation and removing odor while cleaning, and has a sterilizing care function; besides, the sanitary wet tissue has certain treatment and relief effects on gynecological diseases and diseases of men, and is wide in application range.
Orally administered erythromycin ethylsuccinate suspension is readily and reliably absorbed. Comparable serum levels of erythromycin are achieved in the fasting and nonfasting states.

Erythromycin diffuses readily into most body fluids. Only low concentrations are normally achieved in the spinal fluid, but passage of the drug across the blood-brain barrier increases in meningitis. In the presence of normal hepatic function, erythromycin is concentrated in the liver and excreted in the bile; the effect of hepatic dysfunction on excretion of erythromycin by the liver into the bile is not known. Less than 5 percent of the orally administered dose of erythromycin is excreted in active form in the urine.

Erythromycin crosses the placental barrier, but fetal plasma levels are low. The drug is excreted in human milk.
In Part 1, one 30 ug dose of \[14C\]AZD4604 Solution for Infusion 6 ug/mL (NMT 37.0 kBq/5 mL) and one 3 mg dose of AZD4604 Inhalation Powder, 1 mg (as 3 x 1 mg). In Part 2, one 4 mg dose of \[14C\]AZD4604 Oral Solution, 4 mg (NMT 37.0 kBq).
The invention relates to a health-care composition which is composed of Radix Astragali, Radix Codonopsis, wolfberry and malt and can enhance immunity and help fight fatigue and a preparation thereof. According to the composition, edible and pharmaceutical materials are adopted for material selection, compatibility of medicines is scientific, and the production technology is economical and green. According to the invention, Radix Astragali has effects of tonifying qi and strengthening exterior, arresting sweating and relieving desertion, treating sores and carbuncles and engendering flesh and inducing diuresis to alleviate edema; and Radix Codonopsis has effects of supplementing the center and boosting qi and strengthening spleen and tonifying lung. The two medicines, Radix Astragali and Radix Codonopsis, are combined to replenish qi to invigorate the spleen, nourishing the central part, make spleen healthy and vigorous, nourish body and mind and eliminate fatigue. With the addition of wolfberry which is sweet in taste and neutral in nature and has efficacy of tonifying liver and kidney, and with compatibility of malt which has efficacy of helping digestion, tonifying spleen, soothing liver and harmonizing stomach, absorption of each medicine is promoted on one hand, and on the other hand, the combination of the medicines helps sooth the liver and regulate and smooth liver-qi and is beneficial to earthing up. With compatibility of the above four medicines, it helps supplement the center and boost qi, reinforce spleen and stomach, nourish liver and kidney and sooth liver-qi. On one hand, the composition helps tonify deficiency and strengthen yang-qi and nourish the body; and on the other hand, the composition helps make mind comfortable, and compatibility and application of the medicines helps flourish qi, soothe the nerves and eliminate fatigue.
Patient population BETAFLEC-CHIOS, is a single-center registry that was initiated in the "Skylitseion" General Hospital of Chios in January 2020 and is ongoing. Patients are included in the registry if presenting with recent-onset atrial fibrillation (AF) (≤48 hours of onset) and lasting ≥30min, documented by a 12-lead ECG and having received intravenous (IV) flecainide on treating physician's discretion. Exclusion criteria are severe structural or ischemic heart disease (previous cardiac surgery, any cardiomyopathy, myocardial infarction at any time), atrial flutter, sick sinus syndrome, high degree atrioventricular block, bifascicular block, abnormal electrolyte levels (especially hypo- or hyperkalemia) or known sensitivity to flecainide. Continuous monitoring is applied during and after administration of IV flecainide. If no conversion to sinus rhythm is achieved at 2 hours after flecainide infusion initiation, the patient is recorded as "unsuccessful conversion attempt" and forwarded for direct current cardioversion (DCC). All patients were anticoagulated according to the current European Society Guidelines (ESC) or the management of AF \[ESC Afib 2020\].

Flecainide administration Flecainide is given as an IV infusion of 1.5 mg/kg (max 150 mg) in DW 5% over 10 min under continuous monitoring. Concomitant administration of a b-blocker is also applied in all patients. The dose and type of b-blocker are selected according to heart rate during the AF and patient's medical history. "Time to conversion" is calculated as the time interval from the end of the infusion up to when sinus rhythm is observed on the monitor and confirmed subsequently with a 12-lead ECG.